Metabolimic profiling of drug responses in acute myeloid leukemia cell lines

PLoS ONE

Volumn 4, Issue 1, 2009, Pages

  Tiziani, Stefano ^a   Lodi, Alessia ^a   Khanim, Farhat L ^a   Viant, Mark R ^a   Bunce, Christopher M ^a   Günther, Ulrich L ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; MEDROXYPROGESTERONE ACETATE; REACTIVE OXYGEN METABOLITE; ANTINEOPLASTIC AGENT; OXYGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CELL TYPE; CITRIC ACID CYCLE; CONTROLLED STUDY; DOWNSTREAM PROCESSING; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; GENETIC DIFFERENCE; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; METABOLOMICS; NUCLEAR MAGNETIC RESONANCE; PHENOTYPE; TUMOR CELL; CELL DIFFERENTIATION; CELL STRAIN HL 60; CELL STRAIN K 562; DRUG DESIGN; DRUG SCREENING; METABOLISM; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; TIME; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CELL LINE, TUMOR; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; HL-60 CELLS; HUMANS; K562 CELLS; LEUKEMIA, MYELOID, ACUTE; MAGNETIC RESONANCE SPECTROSCOPY; METABOLOMICS; OXYGEN; PHENOTYPE; REACTIVE OXYGEN SPECIES; TIME FACTORS;

EID: 64249158872     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0004251     Document Type: Article

References (38)

1. Chong CR, Sullivan DJ (2007) New uses for old drugs. Nature 448(7154): 645-646.
2. Cohen FJ (2005) Macro trends in pharmaceutical innovation. Nat Rev Drug Discov 4(1): 78-84.
3. DiMasi JA, Hansen RW, Grabowski HG (2003) The price of innovation: new estimates of drug development costs. J Health Econ 22(2): 151-185.
4. Blaise BJ, Giacomotto J, Elena B, Dumas ME, Toullhoat P, et al. (2007) Metabotyping of Caenorhabditis elegans reveals latent phenotypes. Proc Natl Acad Sci USA 104(50): 19808-19812.
5. Bundy JG, Iyer NG, Gentile MS, Hu DE, Kettunen M, et al. (2006) Metabolic consequences of p300 gene deletion in human colon cancer cells. Cancer Res 66(15): 7606-7614.
6. Griffin JL, Shockcor JP (2004) Metabolic profiles of cancer cells. Nat Rev Cancer 4(7): 551-561.
7. Hakumaki JM, Brindle KM (2003) Techniques: Visualizing apoptosis using nuclear magnetic resonance. Trends Pharmacol Sci 24(3): 146-149.
8. Kettunen MI, Brindle KM (2005) Apoptosis detection using magnetic resonance imaging and spectroscopy. Prog Nucl Magn Reson Spectrosc 47(3-4): 175-185.
9. Lutz NW (2005) From metabolic to metabolomic NMR spectroscopy of apoptotic cells. Metabolomics 1(3): 251-268.
10. Fan TWM, Bandura LL, Higashi RM, Lane AN (2005) Metabolomics-edited transcriptomics analysis of Se anticancer action in human lung cancer cells. Metabolomics 1(4): 325-339.
11. Griffin JL, Pole JCM, Nicholson JK, Carmichael PL (2003) Cellular environment of metabolites and a metabonomic study of tamoxifen in endometrial cells using gradient high resolution magic angle spinning H-1 NMR spectroscopy. Biochim Biophys Acta-Gen Subj 1619(2): 151-158.
12. Neves AA, Brindle KM (2006) Assessing responses to cancer therapy using molecular imaging. Biochim Biophys Acta-Rev Cancer 1766(2): 242-261.
13. Serkova NJ, Spratlin JL, Eckhardt SG (2007) NMR-based metabolomics: Translational application and treatment of cancer. Curr Opin Mol Ther 9(6): 572-585.
14. Tallman MS, Gilliland DG, Rowe JM (2005) Drug therapy for acute myeloid leukemia. Blood 106(4): 1154-1163.
15. Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson RM, et al. (2001) Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood 98(5): 1302-1311.
16. Bunce CM, Mountford JC, French PJ, Mole DJ, Durham J, et al. (1996) Potentiation of myeloid differentiation by anti-inflammatory agents, by steroids and by retinoic acid involves a single intracellular target, probably an enzyme of the aldoketoreductase family. Biochim Biophys Acta-Mol Cell Res 1311(3): 189-198.
17. Scatena R, Nocca G, De Sole P, Rumi C, Puggioni P, et al. (1999) Bezafibrate as differentiating factor of human myeloid leukemia cells. Cell Death Differ 6(8): 781-787.
18. Fenton SL, Luong QT, Sarafeim A, Mustard KJW, Pound J, et al. (2003) Fibrates and medroxyprogesterone acetate induce apoptosis of primary Burkitt's lymphoma cells and cell lines: potential for applying old drugs to a new disease. Leukemia 17(3): 568-575.
19. Khanim F, Hayden RE, Birtwistle J, Lodi A, Tiziani S, et al. (2008) Rational redeployment of bezafibrate and medroxyprogesterone acetate as novel therapy for elderly and relapsed acute myeloid leukaemia. submitted.
20. Bundy JG, Papp B, Harmston R, Browne RA, Clayson EM, et al. (2007) Evaluation of predicted network modules in yeast metabolism using NMR-based metabolite profiling. Genome Res 17(4): 510-519.
21. Fukuda M, Koeffler HP, Minowada J (1981) Membrane differentiation in human myeloid cells - Expression of unique profiles of cell-surface glycoproteins in myeloid leukemic cell lines blocked at different stages of differentiation and maturation. Proc Natl Acad Sci USA 78(10): 6299-6303.
22. Schumacker PT (2006) Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer Cell 10(3): 175-176.
23. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, et al. (2005) Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 7(1): 77-85.
24. Brookes PS, Freeman RS, Barone MC (2006) A shortcut to mitochondrial signaling and pathology: a commentary on "Nonenzymatic formation of succinate in mitochondria under oxidative stress". Free Radic Biol Med 41(1): 41-45.
25. Fedotcheva NI, Sokolov AP, Kondrashova MN (2006) Nonenzymatic formation of succinate in mitochondria under oxidative stress. Free Radic Biol Med 41(1): 56-64.
26. Mailloux RJ, Beriault R, Lemire J, Singh R, Chenier DR, et al. (2007) The tricarboxylic acid cycle, an ancient metabolic network with a novel twist. PLoS ONE 2(1): e690.
27. Evans DR, Guy HI (2004) Mammalian pyrimidine biosynthesis: Fresh insights into an ancient pathway. J Biol Chem 279(32): 33035-33038.
28. Martin DS, Bertino JR, Koutcher JA (2000) ATP depletion plus pyrimidine depletion can markedly enhance cancer therapy: Fresh insight for a new approach. Cancer Res 60(24): 6776-6783.
29. Ahmed N, Weidemann MJ (1995) Biochemical effect of 3 different inhibitors of purine/pyrimidine metabolism on differentiation in HL-60 cells. Leuk Res 19(4): 263-273.
30. Gonzalez-Aragon D, Ariza J, Villalba JM (2007) Dicoumarol impairs mitochondrial electron transport and pyrimidine biosynthesis in human myeloid leukemia HL-60 cells. Biochem Pharmacol 73(3): 427-439.
31. Lucas DL, Webster HK, Wright DG (1983) Purine metabolism in myeloid precursor cells during maturation - Studies with the HL-60-cell line. J Clin Invest 72(6): 1889-1900.
32. Wu HF, Southam AD, Hines A, Viant MR (2008) High-throughput tissue extraction protocol for NMR and MS-based metabolomics. Anal Biochem 372(2): 204-212.
33. Aue W, Karhan J, Ernst R (1976) Homonuclear broad-band decoupling and 2-dimensional J-resolved NMR spectroscopy. J Chem Phys 64: 4226-4227.
34. Hwang TL, Shaka AJ (1995) Water suppression that works - Excitation sculpting using arbitrary wave-forms and pulsed-field gradients. J Magn Reson Ser A 112(2): 275-279.
35. Thrippleton MJ, Edden RAE, Keeler J (2005) Suppression of strong coupling artefacts in J-spectra. J Magn Reson 174(1): 97-109.
36. Tiziani S, Lodi A, Ludwig C, Parsons HM, Viant MR (2008) Effects of the application of different window functions and projection methods on processing of H-1 J-resolved nuclear magnetic resonance spectra for metabolomics. Anal Chim Acta 610(1): 80-88.
37. Parsons HM, Ludwig C, Günther UL, Viant MR (2007) Improved classification accuracy in 1-and 2-dimensional NMR metabolomics data using the variance stabilising generalised logarithm transformation. BMC Bioinformatics 8: 234.
38. Günther UL, Ludwig C, Ruterjans H (2000) NMRLAB - Advanced NMR data processing in MATLAB. J Magn Reson 145(2): 201-208.